LEO Pharma’s Major Contribution to Managing Chronic Hand Eczema
At EADV 2024, LEO Pharma A/S, a leading name in the field of medical dermatology, presented groundbreaking data on Anzupgo® (delgocitinib) cream through their DELTA FORCE trial findings. This key event displayed results that might change the treatment landscape for adults suffering from moderate to severe chronic hand eczema (CHE), especially for those who haven't found relief with topical corticosteroids.
Key Findings from the DELTA FORCE Trial
The DELTA FORCE trial was a well-structured, 12-week phase 3 study involving 513 participants. Its primary aim was to compare the effectiveness and safety of delgocitinib cream against oral alitretinoin capsules. The trial results clearly indicated that delgocitinib cream led to a significantly greater improvement in Hand Eczema Severity Index (HECSI) scores compared to the other treatment.
Notable Results of the DELTA FORCE Trial
The key outcome of reduced HECSI scores showed that delgocitinib cream achieved a mean decrease of 67.6—substantially more than the 51.5 decrease noted for alitretinoin (P<0.001). A significant portion of patients using delgocitinib cream also reported successful treatment after 12 weeks, which highlights its superior effectiveness in managing CHE symptoms.
Comprehensive Data Shared at EADV 2024
The insights presented at this congress represented only a small part of LEO Pharma’s broad scientific agenda. In addition to the DELTA FORCE findings, the company released six more abstracts that underscored the complex and diverse nature of CHE.
The Real-World Impact of Chronic Hand Eczema
Real-world data shows that many patients struggle with unique challenges related to the varied nature of CHE, which includes a range of symptoms and possible related health issues. Recent studies offer not only objective trial outcomes but also valuable insights into how CHE impacts patients’ quality of life.
Promising Insights from Additional Research
Among the significant presentations was a post hoc analysis that examined the effectiveness of delgocitinib cream for five different subtypes of CHE. Additionally, a population-based CHECK study illustrated how the quality of life for patients declines with each step in treatment. Qualitative interviews further revealed that nearly all patients feel a substantial burden from living with CHE.
LEO Pharma's Commitment to Advancing CHE Treatments
As the field of dermatology continues to develop, LEO Pharma is committed to addressing the pressing needs related to chronic hand eczema. The possible shift toward delgocitinib cream as a primary treatment option reflects the organization’s dedication to enhancing patient outcomes.
About Anzupgo® (delgocitinib) Cream
Anzupgo® cream, a pan-Janus kinase inhibitor, offers promising advantages for patients dealing with moderate to severe CHE who find traditional topical therapies inadequate. By employing innovative mechanisms, this cream targets crucial inflammatory pathways involved in the development of CHE.
About LEO Pharma
Founded in 1908, LEO Pharma has been a pioneer in making advancements in dermatology. Their long-standing tradition of research and innovation reflects their commitment to the community, resulting in a wide range of treatments for various skin conditions. Based in Denmark, LEO Pharma employs about 4,200 people worldwide, helping millions of patients and posting net sales of DKK 11.4 billion in recent years.
Frequently Asked Questions
What is the DELTA FORCE trial?
The DELTA FORCE trial is a phase 3 clinical study designed to compare the safety and efficacy of delgocitinib cream against oral alitretinoin capsules in adults with severe chronic hand eczema.
What were the key findings of the DELTA FORCE trial?
The trial showed that delgocitinib cream led to a significantly greater reduction in Hand Eczema Severity Index (HECSI) scores than alitretinoin, demonstrating its effectiveness for treating severe chronic hand eczema.
How does Anzupgo® cream work?
Anzupgo® cream acts as a pan-Janus kinase inhibitor, interrupting key inflammatory signaling pathways that are involved in chronic hand eczema.
What significance do the EADV 2024 presentations hold?
The presentations at EADV 2024, including results from various studies, emphasize the urgent need for effective treatments for chronic hand eczema and highlight the innovative efforts of LEO Pharma in this area.
How can patients benefit from delgocitinib cream?
Patients may experience better management of their chronic hand eczema symptoms with delgocitinib cream, supported by clinical data that suggests improved effectiveness and safety compared to existing treatments.
